<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01229267</url>
  </required_header>
  <id_info>
    <org_study_id>V212-001</org_study_id>
    <nct_id>NCT01229267</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Participants Undergoing Hematopoietic Cell Transplants (HCTs) (Study No. V212-001 AM4)</brief_title>
  <official_title>A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoietic Cell Transplants (HCTs)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to determine whether investigational V212 reduces the incidence of herpes
      zoster (HZ) compared to placebo when administered to recipients of autologous hematopoietic
      cell transplants (HCT).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of herpes zoster (HZ)</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>Incidence is defined as the number of HZ cases per 1000 person-years of follow-up from study enrollment to the end of study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of moderate to severe HZ-associated pain</measure>
    <time_frame>From HZ onset through the end of the 6 month HZ-follow-up period</time_frame>
    <description>Moderate to severe HZ-associated pain (defined as 2 or more occurrences of a score of 3 or greater (0-to-10 scale) on the Zoster Brief Pain Inventory [ZBPI]),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of HZ complications</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>HZ complications defined as the occurrence of any of the following during the study: hospitalization or prolongation of hospitalization due to HZ, disseminated HZ (including disseminated HZ rash or VZV viremia), visceral HZ, ophthalmic HZ, neurological impairment due to HZ, or administration of intravenous acyclovir therapy for treatment of HZ.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of postherpetic neuralgia (PHN)</measure>
    <time_frame>Onset of HZ rash up to 6-month follow-up</time_frame>
    <description>Postherpetic neuralgia (PHN) is defined as a worst pain score [in the last 24 hours] of 3 or greater [0-to-10 scale] on the Zoster Brief Pain Inventory (ZBPI) that persists or appears greater than or equal to 90 days after the onset of the HZ rash</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1257</enrollment>
  <condition>Herpes Zoster</condition>
  <arm_group>
    <arm_group_label>V212</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>V212 (inactivated VZV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V212</intervention_name>
    <description>0.5-mL subcutaneous injection administered ~30days (60 to 5 days) prior to HCT. Doses 2 through 4 will be administered 30, 60 and 90 days post-HCT.</description>
    <arm_group_label>V212</arm_group_label>
    <other_name>Inactivated Varicella-Zoster (VZV) vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Matching placebo</intervention_name>
    <description>0.5-mL subcutaneous injection administered ~30days (60 to 5 days) prior to HCT. Doses 2 through 4 will be administered 30, 60 and 90 days post-HCT.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women at least 18 years of age

          -  Has prior history of varicella, antibodies to VZV (documented prior to receipt of
             blood products), or residence in a country with endemic VZV infection for â‰¥30 years or
             if participant is &lt;30 years old, attended primary or secondary school in a country
             with endemic VZV infection.

          -  Scheduled to undergo an autologous hematopoietic cell transplant within 60 days of
             enrollment

          -  Is highly unlikely to conceive during the time period starting 2 weeks prior to
             enrollment through 6 months from last vaccination dose

          -  Female participants of childbearing potential must have a negative serum or urine

        pregnancy test.

        Exclusion Criteria:

          -  History of hypersensitivity reaction to any vaccine component

          -  Prior history of herpes zoster within 1 year of enrollment

          -  Prior receipt of any varicella or zoster vaccine

          -  More than 2 relapses of the underlying cancer (participants with Hodgkin's lymphoma
             may have had more than 2 relapses)

          -  Expectation of tandem transplant procedure

          -  Is expected to receive &gt;6 months (&gt;180 days) of prophylactic antiviral therapy
             post-HCT.

          -  Is pregnant or breastfeeding or expecting to conceive within the period of 2 weeks
             prior to enrollment through 6 months from last vaccination dose.

          -  Has received a live virus vaccine or is scheduled to receive a live virus vaccine in
             the period from 4 weeks prior to Dose 1 through 28 days Postdose 4.

          -  Has received an inactivated vaccine or is scheduled to receive an inactivated vaccine
             in the period between 7 days prior to and 28 days following Doses 1 through 4.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Croatia</country>
    <country>Czech Republic</country>
    <country>Ecuador</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Panama</country>
    <country>Peru</country>
    <country>Portugal</country>
    <country>Puerto Rico</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2010</study_first_submitted>
  <study_first_submitted_qc>October 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2010</study_first_posted>
  <last_update_submitted>July 27, 2016</last_update_submitted>
  <last_update_submitted_qc>July 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Herpes zoster</keyword>
  <keyword>vaccine</keyword>
  <keyword>herpes zoster-related complications</keyword>
  <keyword>immunocompromised</keyword>
  <keyword>autologous hematopoietic cell transplants</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Zoster</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 16, 2018</submitted>
    <returned>May 15, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

